Amylin analogs
Analogs of the beta-cell hormone amylin (e.g. pramlintide, cagrilintide). They slow gastric emptying, blunt postprandial glucagon release and promote satiety — relevant for glucose and weight control, complementary to GLP-1 agents.
Peptides on this topic
6 peptides researched for this topicAmycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes.
- Human RCTIn a randomised phase-1b/2a study, subcutaneous amycretin produced a marked, dose-dependent weight loss with no apparent plateau through week 36.
Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet.
- Human RCTAdditional weight reduction in combination with semaglutide 2.4 mg versus semaglutide monotherapy observed in the phase-2 CagriSema trial
CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes.
- Human RCTIn the phase-3 REDEFINE 2 study (obesity with type 2 diabetes), CagriSema reached a mean weight loss of 15.7% at 68 weeks versus 3.1% on placebo.
Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy.
- Human RCTIn a 48-week phase-2 study, all dose arms met the primary endpoint with mean weight loss of about 9.5% to 20.1% versus 0.4% on placebo.
Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability.
- Human RCTIn the phase-2 ZUPREME-1 study, petrelintide reached a mean weight loss of up to 10.7% (week 42) with strong tolerability.
Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying.
- Human RCTAs an adjunct to insulin therapy, lowers postprandial blood-glucose spikes and modestly reduces HbA1c.